Cosmo Oil, SBI Alapromo Of Japan And German Drug Co. Establish New JV
This article was originally published in PharmAsia News
Japan's Cosmo Oil and SBI Alapromo, along with Germany's Medec GmbH, have signed a deal to establish a joint venture to develop new drugs using aminolevulinic acid. To be established in June, the new company ALA Pharma will have €25,000 in capital investment. SBI Alapromo and Medec will each take a 50 percent stake. Medec obtained approval from the European Medicines Agency for Giolan (5-aminolevulinic) for visualization of malignant tissue during surgery for brain tumors. Cosmo Oil owns 15 percent of SBI Alapromo's total shares. (Click here for more - Japanese language
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.